- All
- Buy
- Hold
- Sell
- Yearly
- Quarterly
| 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | - | - | - | - |
| Dividend | - | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - | - |
| EPS | - | -0.21 | -0.07 | -0.04 | 0.33 | 0.13 |
| P/E Ratio | -8.08 | -10.86 | -32.57 | -57.00 | 6.91 | 17.54 |
| EBIT | - | -16 | -11 | -12 | 38 | 9 |
| EBITDA | - | - | - | - | - | - |
| Net Profit | - | -15 | -7 | -4 | 33 | 13 |
| Net Profit Adjusted | - | - | - | - | - | - |
| Pre-Tax Profit | - | -15 | -7 | -4 | 45 | 18 |
| Net Profit (Adjusted) | - | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - | - |
| EPS (GAAP) | - | - | - | - | - | - |
| Gross Income | - | - | - | - | - | - |
| Cash Flow from Investing | - | 21 | - | - | - | - |
| Cash Flow from Operations | - | 23 | 64 | -7 | 30 | 10 |
| Cash Flow from Financing | - | 21 | - | - | - | - |
| Cash Flow per Share | - | 0.31 | 0.87 | -0.10 | 0.40 | 0.13 |
| Free Cash Flow | - | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - | - |
| Book Value per Share | - | 0.62 | 1.47 | 1.34 | 1.72 | 1.83 |
| Net Debt | - | - | - | - | - | - |
| Research & Development Exp. | - | 11 | 11 | 12 | 12 | 12 |
| Capital Expenditure | - | 0 | - | - | - | - |
| Selling, General & Admin. Exp. | - | - | - | - | - | - |
| Shareholder’s Equity | - | 46 | 108 | 99 | 127 | 135 |
| Total Assets | - | - | - | - | - | - |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 03/31/25 | Next Year | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | - | - | 2 | 1 |
| Average Estimate | - | - | - | -0.210 CAD | -0.070 CAD |
| Year Ago | - | - | - | -0.366 CAD | - |
| Publish Date | - | - | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | - | - | 2 | - |
| Average Estimate | - | - | - | 0 CAD | - |
| Year Ago | - | - | - | 0 CAD | - |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2024 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2023 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2022 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2021 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2020 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2019 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2018 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2017 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
| 2016 | Medicenna Therapeutics Corp Registered Shs | 0.00 | 0.00 | CAD |
*Yield of the Respective Date
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
| Owner | in % |
|---|---|
| Freefloat | 77.36 |
| Fahar Merchant, PhD | 7.56 |
| Rosemina Merchant | 7.35 |
| Aries Biologics, Inc. | 7.22 |
| RA Capital Management LP | 6.92 |
| AIGH Capital Management LLC | 6.13 |
| AIGH Capital Management LLC | 5.70 |
| Worth Venture Partners LLC | 1.43 |
| AWM Investment Co., Inc. | 1.31 |
| Hudson Bay Capital Management LP | 1.02 |
| DAFNA Capital Management LLC | 0.87 |
| Alyeska Investment Group LP | 0.85 |
| Sigma Planning Corp. | 0.83 |
| Empery Asset Management LP | 0.77 |
| Verition Fund Management LLC | 0.73 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcLnDp5ifZaOpvKS3